CRISPR Therapeutics
CRSP
398 hedge funds and large institutions have $2.46B invested in CRISPR Therapeutics in 2022 Q4 according to their latest regulatory filings, with 57 funds opening new positions, 117 increasing their positions, 120 reducing their positions, and 87 closing their positions.
27% more call options, than puts
Call options by funds: $109M | Put options by funds: $86.2M
3% less repeat investments, than reductions
Existing positions increased: 117 | Existing positions reduced: 120
1.78% less ownership
Funds ownership: 72.71% → 70.92% (-1.8%)
9% less funds holding
Funds holding: 436 → 398 (-38)
34% less capital invested
Capital invested by funds: $3.7B → $2.46B (-$1.25B)
34% less first-time investments, than exits
New positions opened: 57 | Existing positions closed: 87
63% less funds holding in top 10
Funds holding in top 10: 8 → 3 (-5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$39.9M |
| 2 |
State Street
Boston,
Massachusetts
|
+$27.2M |
| 3 |
BlackRock
New York
|
+$15M |
| 4 |
Barclays
London,
United Kingdom
|
+$14.9M |
| 5 |
PI
PEAK6 Investments
Chicago,
Illinois
|
+$14.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$55.4M |
| 2 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$42.3M |
| 3 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$21.6M |
| 4 |
IHAM
Integral Health Asset Management
New York
|
-$14.4M |
| 5 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
-$14M |
CRSP Hedge Fund Activity: Q4 2022 in Review
398 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in CRISPR Therapeutics (CRSP) for Q4 2022, worth a combined $2.46B — down 34% from $3.7B a quarter earlier.
Sellers outnumbered buyers: 87 funds closed out of CRSP and 57 opened new positions — a net loss of 30 holders — while 120 trimmed existing stakes and 117 added.
The largest buyer was T. Rowe Price Investment Management, adding an estimated $39.9M. The largest seller was Bank of America, cutting an estimated $55.4M.
- 398 institutional investors held CRISPR Therapeutics (CRSP) as of Q4 2022, down from 436 in Q3 2022.
- Funds reported $2.46B of CRISPR Therapeutics stock for Q4 2022, down 34% quarter-over-quarter.
- 57 funds opened new CRISPR Therapeutics positions in Q4 2022 and 87 closed out, a net change of -30 holders.
- The largest CRISPR Therapeutics buyer in Q4 2022 was T. Rowe Price Investment Management, an estimated $39.9M added.
- The largest CRISPR Therapeutics seller in Q4 2022 was Bank of America, an estimated $55.4M sold.
Based on aggregated 13F filings for Q4 2022.